广西城市民族工作调研报告

随着经济社会的发展 ,城市中定居与流动的民族成份和少数民族人口将会越来越多 ,城市民族工作将越来越复杂 ,其地位也显得越来越重要。此调研报告总结了近年来广西城市民族工作的主要成就 ,分析了新形势下城市民族工作的特点和存在的主要问题 ,探索了做好城市民族工作的新途径。     

广西依靠科技发展现代农业的实践与思考

文章通过对广西依靠科技发展现代农业的典型调查及建设现代农业示范区的具体实践 ,阐述发展现代农业必须充分依靠科学技术 ,必须采取有效措施 ,包括正确制定农业科技政策 ,深化农业科技体制改革 ,发挥科技人员和农民应用现代科技的能力以及增加农业的科技投入 ,才能真正促进现代农业的发展和跨越。     

p33.4位点扩增片段长度多态性及其法医学应用的研究

以聚合酶链反应（PCR）、聚丙烯酰胺凝胶垂直电泳和银染法对中国100名无关个体小卫星区域p33．4位点的扩增片段长度多态性（Amp－FLPs）进行了研究，检出了8个等位基因。通过BIOTRAC系统进行数据处理．各等位基因重复单位的数目分别为7、10到15，其中在13～14之间发现一差值不足一个重复单位长度的罕见等位基因。片段长度分布于603～1115bP之间，基因频率分布于0.5～33．5％间，杂合度为64％，DP值为84．5％。对5个家庭25名相关个体进行分析，符合孟德尔遗传定律；对同一个体不同组织的DNA进行P33.4位点的分型研究表明，该技术适宜于法医物证检验。此外，本研究以Chelex处理不同检材制备DNA模板用于扩增，率先建立了比常规方法更快、更简便、更为实用的检验方法。     

红塔集团推进"两烟"产业化经营的成功实践及其启示

把烟叶产区作为"第一车间"建设,牢牢抓住烟草企业价值链中的战略性环节,加上"公司+农户"的制度创新和"三合一"的管理体制,逐步走上"原料形成优势、技术提升优势、资本增值优势、管理转化优势、市场实现优势"的扩张发展之路,这是红塔烟草王国崛起的奥秘所在,也为我国农业产业化经营提供了成功的范例.     

中国人类学研究50年回顾

人类学在中国已经走过了近一个世纪的历程.前半世纪是人类学从西方传入中国,开始起步发展和传播的时期,在"抗战"前后达到中国人类学研究的第一个峰值;后半世纪中国人类学经历了坎坷曲折的发展过程,在文化大革命期间跌落至谷底,本世纪80年代,中国人类学研究重获新生,并于90年代后期在中国学术界的影响与日俱增.经历了大起大落之后,中国人类学在面向21世纪之时,在新的起点上正逐渐走向规范化、体系化及本土化,并以崭新的姿态准备充实现代国际人类学的理论和方法、为中国人类学研究做出相应的贡献.回顾和反思这一历程将有助于我们进一步深刻地认识中国人类学的历史地位、社会价值及总结经验教训,为中国人类学在新世纪的发展提供借鉴和建设性的参考意见.     

DNA Commission of the International Society of Forensic Genetics (ISFG): an update of the recommendations on the use of Y-STRs in forensic analysis

The DNA Commission of the International Society of Forensic Genetics (ISFG) regularly publishes guidelines and recommendations concerning the application of DNA polymorphisms to the problems of human identification. A previous recommendation published in 2001 has already addressed Y-chromosome polymorphisms, with particular emphasis on short tandem repeats (STRs). Since then, the use of Y-STRs has become very popular, and a numerous new loci have been introduced. The current recommendations address important aspects to clarify problems regarding the nomenclature, the definition of loci and alleles, population genetics and reporting methods.     

Medicare and Medicaid programs; programs of all-inclusive care for the elderly (PACE); program revisions. Final rule

This rule finalizes the interim final rule with comment period published in the Federal Register November 24, 1999 (64 FR 66234) and the interim final rule with comment period published in the Federal Register on October 1, 2002 (67 FR 61496). The November 1999 interim final rule implemented sections 4801 through 4803 of the Balanced Budget Act of 1997 (Pub. L. 105-33) and established requirements for Programs of All-inclusive Care for the Elderly (PACE) under the Medicare and Medicaid programs. The interim final rule with comment period published on October 1, 2002 (67 FR 61496) implemented section 903 of the Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000 (BIPA) (Pub. L. 106-554).     

Blood vessels recovered with organs and intended for use in organ transplantation. Direct final rule

The Health Resources and Services Administration (HRSA) and the Food and Drug Administration (FDA) are amending their regulations to consider as part of an organ those blood vessels recovered with the organ that are intended for use in organ transplantation (HRSA regulation); and to exclude such blood vessels from the definition of human cells, tissues, and cellular and tissue-based products (HCT/Ps) (FDA regulation). We (HRSA and FDA) are taking this action to provide that blood vessels recovered with organs and intended for use in organ transplantation are governed by the regulations pertaining to organs. The regulation of other recovered blood vessels remains unchanged. We believe that this change will eliminate the unnecessary burden resulting from an organ procurement organization's efforts to comply with both FDA and HRSA rules with respect to blood vessels (FDA jurisdiction) and organs (HRSA jurisdiction). We are issuing these amendments directly as a final rule because they are noncontroversial, and there is little likelihood that we will receive any significant adverse comments. Elsewhere in this issue of the Federal Register, we are publishing a companion proposed rule under our usual procedures for notice and comment in the event that we receive any significant adverse comments on the direct final rule. If we receive any significant adverse comments that warrant terminating the direct final rule, we will consider such comments on the proposed rule in developing the final rule.